Compare Royal Caribbean Cruises Ltd (RCL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs 10X Genomics Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 7.5× 10X Genomics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and 10X Genomics Inc for 91 Days on average.
| RCL | TXG | |
|---|---|---|
Market Cap | $75.26B | $10.07B |
Volume | 1,958,628 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $97.74 |
52-Week Low | $230.30 | $11.48 |
Typical Hold Time | 85 Days | 91 Days |
Enterprise Value | $97.91B | $9.59B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, down 0.35% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with 2025 revenue of $17.93B and net income of $4.27B, representing a 23.54% margin. Recent Q2 2026 earnings beat expectations at $4.21 EPS versus $3.98 expected, while the company expands into resorts through a $3B Sandals stake acquisition announced September 2026.
RCL presents a compelling growth story with improving profitability and strategic expansion, though elevated valuation multiples and high debt levels warrant caution. Analyst consensus remains bullish with a $346.67 price target representing 23% upside potential, but investors should monitor execution risks from the Sandals integration and sensitivity to fuel costs projected at $1.34B for 2026.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
